Oxford Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Oxford Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-80,776	Closed	-$284K	–	496
2026 Q1	$284K	Buy	+80,776	New	+$258K	0.11%	278
2019 Q2	–	Sell	-23,859	Closed	-$227K	–	1837
2019 Q1	$227K	Sell	23,859 -87,613	-79%	-$851K	﹤0.01%	1483
2018 Q4	$987K	Buy	+111,472	New	+$1.08M	0.03%	875
2018 Q3	–	Sell	-85,065	Closed	-$1.11M	–	1803
2018 Q2	$1.11M	Sell	85,065 -45,873	-35%	-$670K	0.02%	982
2018 Q1	$2.21M	Sell	130,938 -27,560	-17%	-$417K	0.05%	518
2017 Q4	$1.28M	Buy	+158,498	New	+$1.27M	0.03%	814
2017 Q2	–	Sell	-39,926	Closed	-$297K	–	1582
2017 Q1	$297K	Sell	39,926 -60,256	-60%	-$442K	0.01%	1205
2016 Q4	$696K	Sell	100,182 -227,251	-69%	-$1.56M	0.02%	538
2016 Q3	$2.69M	Sell	327,433 -81,626	-20%	-$690K	0.08%	337
2016 Q2	$3.31M	Sell	409,059 -195,328	-32%	-$1.23M	0.11%	249
2016 Q1	$3.07M	Buy	604,387 +326,203	+117%	+$1.79M	0.09%	283
2015 Q4	$2.15M	Buy	+278,184	New	+$1.93M	0.05%	384

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Oxford Asset Management's IOVA Position: Q2 2026 in Review

Oxford Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 80,776 shares — an estimated $284K sold.

Oxford Asset Management first reported a position in IOVA in Q4 2015 and held it in 12 quarters. The position peaked at $3.31M in Q2 2016. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Oxford Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Oxford Asset Management sold 80,776 Iovance Biotherapeutics shares in Q2 2026, an estimated $284K.
Oxford Asset Management first reported a position in Iovance Biotherapeutics in Q4 2015 and held it in 12 quarters.
Oxford Asset Management's Iovance Biotherapeutics position peaked at $3.31M in Q2 2016.
293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.